These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31197662)

  • 41. Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.
    Sangroongruangsri S; Kittrongsiri K; Charatcharoenwitthaya P; Sobhonslidsuk A; Chaikledkaew U
    Clinicoecon Outcomes Res; 2021; 13():703-715. PubMed ID: 34349534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of rotavirus vaccination in Albania.
    Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
    Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of rotavirus vaccination in Turkey.
    Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
    J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic evaluation of routine infant rotavirus immunisation program in Japan.
    Hoshi SL; Kondo M; Okubo I
    Hum Vaccin Immunother; 2017 May; 13(5):1115-1125. PubMed ID: 27763810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
    Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
    Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis.
    Connolly MP; Topachevskyi O; Standaert B; Ortega O; Postma M
    Pharmacoeconomics; 2012 Aug; 30(8):681-95. PubMed ID: 22788259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
    Yamin D; Atkins KE; Remy V; Galvani AP
    Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.
    Kittiratchakool N; Kulpokin D; Chanjam C; Vilaiyuk S; Charuvanij S; Phongsamart G; Khaosut P; Tanya M; Nanagara R; Nantapaisarn S; Leelahavarong P
    BMJ Open; 2020 Sep; 10(9):e037588. PubMed ID: 32933962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic evaluation of peritoneal dialysis and hemodialysis in Thai population with End-stage Kidney Disease.
    Assanatham M; Pattanaprateep O; Chuasuwan A; Vareesangthip K; Supasyndh O; Lumpaopong A; Susantitaphong P; Limkunakul C; Ponthongmak W; Chaiyakittisopon K; Thakkinstian A; Ingsathit A
    BMC Health Serv Res; 2022 Nov; 22(1):1384. PubMed ID: 36411422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.
    Wang XJ; Saha A; Zhang XH
    Cost Eff Resour Alloc; 2017; 15():17. PubMed ID: 28852326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
    Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
    Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
    Milne RJ; Grimwood K
    Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Varicella vaccination in Italy : an economic evaluation of different scenarios.
    Coudeville L; Brunot A; Giaquinto C; Lucioni C; Dervaux B
    Pharmacoeconomics; 2004; 22(13):839-55. PubMed ID: 15329030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium.
    Bilcke J; Van Damme P; Beutels P
    Med Decis Making; 2009; 29(1):33-50. PubMed ID: 18948433
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.
    Holubar M; Stavroulakis MC; Maldonado Y; Ioannidis JP; Contopoulos-Ioannidis D
    PLoS One; 2017; 12(3):e0172414. PubMed ID: 28249046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned.
    Pereira P; Vetter V; Standaert B; Benninghoff B
    Expert Rev Vaccines; 2020 Aug; 19(8):755-769. PubMed ID: 32729747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.